iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) Reaches New 1-Year High – Here’s What Happened

Shares of iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $105.15 and last traded at $104.90, with a volume of 14303 shares traded. The stock had previously closed at $103.08.

iShares U.S. Pharmaceuticals ETF Stock Up 1.7%

The firm has a market capitalization of $1.68 billion, a price-to-earnings ratio of 17.75 and a beta of 0.48. The business’s fifty day moving average is $99.43 and its 200 day moving average is $92.29.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Heritage Oak Wealth Advisors LLC acquired a new stake in shares of iShares U.S. Pharmaceuticals ETF in the first quarter valued at approximately $530,000. D.A. Davidson & CO. acquired a new position in iShares U.S. Pharmaceuticals ETF during the fourth quarter worth $1,709,000. Prevail Innovative Wealth Advisors LLC bought a new position in iShares U.S. Pharmaceuticals ETF in the fourth quarter valued at $4,529,000. Bank of America Corp DE grew its position in iShares U.S. Pharmaceuticals ETF by 2.8% in the first quarter. Bank of America Corp DE now owns 456,606 shares of the company’s stock valued at $39,579,000 after purchasing an additional 12,565 shares in the last quarter. Finally, Lee Johnson Capital Management LLC acquired a new stake in iShares U.S. Pharmaceuticals ETF in the 1st quarter valued at $1,603,000.

iShares U.S. Pharmaceuticals ETF Company Profile

iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.